false
2023-08-01
0001617765
00-0000000
Salona Global Medical Device Corp.
0001617765
2023-08-01
2023-08-01
0001617765
dei:FormerAddressMember
2023-08-01
2023-08-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 1, 2023
SALONA GLOBAL MEDICAL DEVICE CORP.
(Exact name of registrant as specified in its charter)
British Columbia
|
333-255642
|
Not Applicable |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
49 Natcon Dr
Shirley, New York, United States
11967
(Address of principal executive offices) (ZIP Code)
Registrant’s telephone number, including area code: (800) 760-6826
3330 Caminito Daniella
Del Mar, California, 92014
United States
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 28, 2023, Salona Global Medical Device Corporation (the "Company") and Lana Newishy agreed that, effective as of August 1, 2023 Lana Newishy's position with the Company was changed from Executive Vice Chair of the Company's Board of Directors to Non-Executive Vice Chair of the Company's Board of Directors.
In connection with her becoming Non-Executive Vice Chair of the Company's Board of Directors the Company and Ms. Newishy agreed to amend the fixed payment component of her compensation package to provide that Ms. Newishy would be paid an hourly rate.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
|
SALONA GLOBAL MEDICAL DEVICE CORPORATION |
|
|
Date: August 3, 2023 |
By: /s/ Dennis Nelson |
|
Name: Dennis Nelson Title: Chief Financial Officer |